Justin Klein, MD, JD

Partner, Washington DC

Justin joined NEA in 2006 and is a Partner on the healthcare team. He focuses on medical device, healthcare technology, and biopharmaceutical company investments. He serves as a director of Advanced Cardiac Therapeutics, Ajax Vascular, Cartiva, PhaseBio Pharmaceuticals, Relievant Medsystems, Senseonics, Topera, Ulthera, VertiFlex, and VytronUS, and has co-sponsored NEA's investments in Carticept Medical, ExploraMed, Moximed, NeuroPace, and Nevro.  Justin’s past board memberships and investments include CV Ingenuity (acquired by Covidien) and TriVascular (NASDAQ: TRIV).  He is also a member of the advisory boards for the National Venture Capital Association’s Medical Industry Group and its Medical Innovation and Competitiveness Coalition (MedIC).

Prior to NEA, Justin worked for the Duke University Health System—reporting directly to the hospital CEO on health system strategy, finance and clinical service unit operations—as Duke built one of the nation's first and largest healthcare integrated delivery systems. Justin concurrently earned his MD from the Duke University School of Medicine and his JD from Harvard Law School. He has also served as a member of the Board of Trustees of Duke University, where he earned his AB in Economics and his BS in Biological Anthropology and Anatomy.